Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA approved.

In pancreatic cancer, pelareorep previously demonstrated a strong efficacy signal when administered with gemcitabine, nab-paclitaxel and atezolizumab. Our new safety data indicate its ability to also ...

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...

Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated ...

Bearish flow noted in AstraZeneca (AZN) with 1,547 puts trading, or 1.9x expected. Most active are 2/14 weekly 68 puts and Feb-25 70 puts, with ...

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...